NCT06380309View on ClinicalTrials.gov

A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

October 30, 2027

Conditions
Advanced Malignant Solid Tumor of Digestive System
Interventions
BIOLOGICAL

IDOV-SAFE

Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER